Neurocrine Biosciences

AbbVie announces IIb data of elagolix for heavy menstrual bleeding

Tuesday, April 11, 2017

AbbVie, a global biopharmaceutical company in cooperation with Neurocrine Biosciences, announced detailed results from a phase IIb clinical trial evaluating the efficacy and safety of elagolix alone or in combination with add-back therapy (estradiol/norethindrone acetate) compared to placebo. The data demonstrated that elagolix, with and without add-back therapy, met the primary efficacy endpoint of reduced heavy menstrual bleeding as compared to placebo (p<0.001). These results were shared for the first time in an oral presentation at the third Congress of the Society of Endometriosis and Uterine Disorders (SEUD) in Singapore.

[Read More]

Neurocrine Biosciences expands clinical pipeline

Thursday, December 11, 2014

Neurocrine Biosciences has announced that NBI-77860, a proprietary corticotropin releasing factor 1 (CRF) receptor antagonist, has entered clinical trials for the treatment of classic congenital adrenal hyperplasia (CAH) a disease that affects approximately 20,000-30,000 people in the U.S. The company has successfully completed a pilot clinical trial in adults with classic CAH and is initiating an open-label, single ascending dose trial in approximately 15 adolescent females with classic CAH, the 1401 Study.

[Read More]